Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:15 06/09/2024 BST			5-day change	1st Jan Change
274.20 ^CHF	-0.72%		-4.53%	+12.15%

09-06	Swiss Stocks End Week in Red; All Eyes on US Jobs Report	MT
09-06	ROCHE HOLDINGS AG : Berenberg sticks Neutral	ZD

ROCHE HOLDINGS AG : Gets a Neutral rating from Jefferies

August 01, 2024 at 10:00 am

In a research note published by Peter Welford, Jefferies gives a Neutral rating to the stock. The target price has been raised from CHF 250 to CHF 270.

Latest news about Roche Holding AG

Swiss Stocks End Week in Red; All Eyes on US Jobs Report	09-06	MT
ROCHE HOLDINGS AG : Berenberg sticks Neutral	09-06	ZD
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	09-06	ZD
Swiss Equities Remain in the Red Amid Regional Retreat	09-04	MT
Roche: new positive data for fenebrutinib	09-04	CF
Roche's Investigational Multiple Sclerosis Drug Shows Disease Activity Suppression in Mid-stage Trial	09-04	MT
Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis	09-04	CI
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	09-03	ZD
ROCHE HOLDINGS AG : Bernstein maintains a Buy rating	08-29	ZD
Swiss Equities Close in the Red; Roche Sheds 1%	08-27	MT
Roche: approval from Brussels for HPN	08-27	CF
Roche's Paroxysmal Nocturnal Haemoglobinuria Treatment Wins EU Approval	08-27	MT
Roche?s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH	08-27	CI
Roche Gets EU Approval for Blood Disorder Injection PiaSky	08-27	DJ
Roche 'Actively Working' to Boost Mpox Lab Testing Capacity Globally	08-20	MT
Roche: mobilized against simian smallpox	08-20	CF
Swiss Industrial Output Rebound Lifts Local Shares	08-16	MT
Roche Gains Swissmedic Nod for Subcutaneous Form of Tecentriq	08-16	MT
Nasdaq's wild mood swings	08-08
Page Industries Limited Announces Change in Directorate	08-08	CI
Biotech firm Recursion to buy smaller peer Exscientia for $688 million	08-08	RE
Swiss Stocks Jump on Signs of Improving Economic Outlook	08-07	MT
Global markets live: Walt Disney, Airbnb, Lyft, Redditt, Amgen...	08-07
Roche: may sell Flatiron Health	08-07	CF
Roche Mulls Options for US-based Cancer Data Unit as Sales Disappoint	08-07	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Employees

103,605

Sector

Pharmaceuticals

Calendar

13/09/2024 - European Association for the Study of Diabetes Meeting

Related indices

SMI , STOXX Europe 600 Index (EUR)

More about the company